Genetic moderation of the effects of cannabis: Catechol-O-methyltransferase (COMT) affects the impact of Δ 9 -tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences
Restricted accessResearch articleFirst published online November, 2015
Genetic moderation of the effects of cannabis: Catechol-O-methyltransferase (COMT) affects the impact of Δ 9 -tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences
Cannabis use can induce cognitive impairments and psychotic experiences. A functional polymorphism in the catechol-O-methyltransferase (COMT) gene (Val158Met) appears to influence the immediate cognitive and psychotic effects of cannabis, or ∆9-tetrahydrocannabinol (THC), its primary psychoactive ingredient. This study investigated the moderation of the impact of experimentally administered THC by COMT. Cognitive performance and psychotic experiences were studied in participants without a psychiatric diagnosis, using a between-subjects design (THC vs. placebo). The effect of COMT Val158Met genotype on the cognitive and psychotic effects of THC, administered intravenously in a double-blind, placebo-controlled manner to 78 participants who were vulnerable to paranoia, was examined. The results showed interactive effects of genotype and drug group (THC or placebo) on working memory, assayed using the Digit Span Backwards task. Specifically, THC impaired performance in COMT Val/Val, but not Met, carriers. In contrast, the effect of THC on psychotic experiences, measured using the Community Assessment of Psychic Experiences (CAPE) positive dimension, was unaffected by COMT genotype. This study is the largest to date examining the impact of COMT genotype on response to experimentally administered THC, and the first using a purely non-clinical cohort. The data suggest that COMT genotype moderates the cognitive, but not the psychotic, effects of acutely administered THC.
AlemanySAriasBFatjo-VilasM. (2014) Psychosis-inducing effects of cannabis are related to both childhood abuse and COMT genotypes. Acta Psychiatr Scand129: 54–62.
2.
ArseneaultLCannonMWittonJ. (2004) Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry184: 110–117.
3.
BarnettJHJonesPBRobbinsTW. (2007) Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: A meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Mol Psychiatry12: 502–509.
4.
BarnettJHScorielsLMunafoMR (2008) Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry64: 137–144.
5.
CasadioPFernandesCMurrayRM. (2011) Cannabis use in young people: The risk for schizophrenia. Neurosci Biobehav Rev35: 1779–1787.
6.
CaspiAMoffittTECannonM. (2005) Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry57: 1117–1127.
7.
ChenJLipskaBKHalimN. (2004) Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet75: 807–821.
8.
Di FortiMMorganCDazzanP. (2009) High-potency cannabis and the risk of psychosis. Br J Psychiatry195: 488–491.
9.
EfronBTibshiraniRJ (1993) An Introduction to the Bootstrap. Chapman and Hall: London.
10.
EganMFGoldbergTEKolachanaBS. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A98: 6917–6922.
11.
FarrellSMTunbridgeEMBraeutigamSHarrisonPJ (2012) COMT Val(158)Met genotype determines the direction of cognitive effects produced by catechol-o-methyltransferase inhibition. Biol Psychiatry71: 538–544.
12.
FreemanDDunnGMurrayRM. (2015) How cannabis causes paranoia: Using the intravenous administration of 9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull41: 391–399.
13.
Goldman-RakicPSMulyEC3rdWilliamsGV (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev31: 295–301.
14.
GothelfDLawAJFrischA. (2014) Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome. Biol Psychiatry75: 406–413.
15.
GreenCEFreemanDKuipersE. (2008) Measuring ideas of persecution and social reference: The Green et al. Paranoid Thought Scales (GPTS). Psychol Med38: 101–111.
16.
HenquetCKrabbendamLSpauwenJ. (2005) Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ330: 11.
17.
HenquetCRosaADelespaulP. (2009) COMT ValMet moderation of cannabis-induced psychosis: A momentary assessment study of ‘switching on’ hallucinations in the flow of daily life. Acta Psychiatr Scand119: 156–160.
18.
HenquetCRosaAKrabbendamL. (2006) An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology31: 2748–2757.
19.
KaufmannRMKraftBFreyR. (2010) Acute psychotropic effects of oral cannabis extract with a defined content of Delta9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry43: 24–32.
20.
MierDKirschPMeyer-LindenbergA (2010) Neural substrates of pleiotropic action of genetic variation in COMT: A meta-analysis. Mol Psychiatry15: 918–927.
21.
MooreTHZammitSLingford-HughesA. (2007) Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet370: 319–328.
22.
MorrisonPDZoisVMcKeownDA. (2009) The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med39: 1607–1616.
23.
NaefMRussmannSPetersen-FelixS. (2004) Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci93: 1176–1184.
24.
PapaleoFCrawleyJNSongJ. (2008) Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci28: 8709–8723.
25.
RanganathanMD’SouzaDC (2006) The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology (Berl)188: 425–444.
26.
StumpenhorstKKäenmäkiMHarrisonPJ. (2012) Catechol-O-methyltransferase (COMT) inhibition and D-9-tetrahydrocannabinol (THC) have interactive effects on dopamine levels in the nucleus accumbens. J Psychopharm26: A64.
27.
TunbridgeEMBannermanDMSharpT. (2004) Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci24: 5331–5335.
28.
TunbridgeEMHarrisonPJWeinbergerDR (2006) Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry60: 141–151.
29.
UNODC (2013) World Drug Report. United Nations Publications. Vol Sales No. E.13.XI.6.
30.
van WinkelR (2011) Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. Arch Gen Psychiatry68: 148–157.
31.
Verdejo-GarciaAFagundoABCuencaA. (2013) COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users. Neuropsychopharmacology38: 1598–1606.
32.
VinkersCHVan GastelWASchubartCD. (2013) The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val(1)(5)(8)Met polymorphism. Schizophr Res150: 303–311.
33.
YavichLForsbergMMKarayiorgouM. (2007) Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci27: 10196–10209.
